Kriya Therapeutics joined the Unicorn Club after raising $921.3 million across multiple funding rounds, reaching a $2 billion valuation. Founded in 2019 and headquartered in Palo Alto, California, United States, Kriya Therapeutics is a biotechnology company focused on developing gene therapies for chronic and complex diseases.
The company applies advanced vector engineering and gene delivery technologies to address conditions with significant unmet medical need.
Keep reading to learn how Kriya Therapeutics scaled into a $2 billion gene therapy unicorn.
What Is Kriya Therapeutics and What Does It Do?
Founded in 2019, Kriya Therapeutics is a biotechnology company developing gene therapies aimed at treating chronic diseases. The company focuses on liver directed and ocular gene therapies, leveraging proprietary capsid engineering and gene delivery platforms.
Kriya Therapeutics builds long lasting therapeutic solutions designed to provide sustained protein expression with a single administration. Its pipeline targets diseases across metabolic, ophthalmologic, and other chronic indications, positioning the company at the intersection of gene therapy innovation and clinical development.
How Much Funding Has Kriya Therapeutics Raised?
1. Seed Round
- Amount Raised: $20 million
- Date: 2019
- Lead Investors: Atlas Venture
- Purpose: Establish gene therapy platform and initiate early research programs
2. Series A Round
- Amount Raised: $80 million
- Date: 2020
- Lead Investors: Atlas Venture, TCG Crossover
- Purpose: Advance preclinical programs and expand scientific team
3. Series B Round
- Amount Raised: $165 million
- Date: 2021
- Lead Investors: Bain Capital Life Sciences, Samsara BioCapital
- Purpose: Progress multiple gene therapy candidates into clinical development
4. Series C Round
- Amount Raised: $270 million
- Date: 2022
- Lead Investors: Bain Capital Life Sciences, Samsara BioCapital
- Purpose: Support late stage clinical trials and expand manufacturing capabilities
5. Series D Round
- Amount Raised: $386.3 million
- Date: 2023
- Valuation: Approximately $2 billion
- Lead Investors: Bain Capital Life Sciences
- Purpose: Advance pivotal trials, scale commercialization readiness, and expand pipeline
Total Funding Raised: $921.3 million Latest Funding Date: 2023 Latest Known Valuation: $2 billion
Key Investors
- Bain Capital Life Sciences
- Details: Life sciences focused investment firm
- Focus Areas: Biotechnology, therapeutics, and clinical stage innovation
- Samsara BioCapital
- Details: Venture capital firm focused on biotech and life sciences
- Focus Areas: Drug development, gene therapy, and platform technologies
- Atlas Venture
- Details: Early stage venture capital firm
- Focus Areas: Biotechnology company creation and innovation
- TCG Crossover
- Details: Growth stage investment firm
- Focus Areas: Life sciences and healthcare innovation
Where Is Kriya Therapeutics’ Headquarters?
Kriya Therapeutics is headquartered in Palo Alto, California, United States, serving as the center for its research, clinical development, and gene therapy operations.
What’s Next for Kriya Therapeutics?
Kriya Therapeutics plans to advance its gene therapy programs through late stage clinical trials and prepare for commercialization. The company is focused on expanding its pipeline, optimizing vector technologies, and pursuing regulatory approvals for therapies targeting chronic diseases. Continued investment in manufacturing and clinical execution positions Kriya Therapeutics for long term impact in gene based medicine.
Get Investor and Funding Insights with TexAu
TexAu helps you track verified investor activity, funding rounds, and company growth signals across high growth startups like Kriya Therapeutics. Discover actionable insights on biotechnology companies, gene therapy platforms, and life sciences investment trends.
Sign up for Free to unlock real time investor and funding intelligence.